Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Reiko Miyazawa is active.

Publication


Featured researches published by Reiko Miyazawa.


Brain & Development | 2001

Plasmapheresis in fulminant acute disseminated encephalomyelitis

Reiko Miyazawa; Akio Hikima; Yoko Takano; Hirokazu Arakawa; Takeshi Tomomasa; Akihiro Morikawa

We report an 11-year-old girl with acute disseminated encephalomyelitis (ADEM) who developed respiratory failure and coma despite the use of corticosteroid and intravenous immunoglobulin. We performed plasmapheresis four times, which improved her level of consciousness, hyperesthesia, external ophthalmoplegia and muscle weakness, and led to the normalization of brain and spinal cord MRI. Plasmapheresis might be an effective treatment in cases of fulminant ADEM.


Pediatrics International | 2002

Prevalence of gastro-esophageal reflux-related symptoms in Japanese infants

Reiko Miyazawa; Takeshi Tomomasa; Hiroaki Kaneko; Atsushi Tachibana; Tetsushi Ogawa; Akihiro Morikawa

Background : To obtain precise information on the natural course of gastro‐esophageal reflux (GER)‐related symptoms in Japanese children, we surveyed the prevalence of regurgitation or vomiting and other GER‐related symptoms and complications in infants visiting for healthy baby check‐ups.


Pediatrics International | 2003

Determinants of prognosis of acute transverse myelitis in children

Reiko Miyazawa; Yuka Ikeuchi; Takeshi Tomomasa; Hideo Ushiku; Tetsushi Ogawa; Akihiro Morikawa

Background : Acute transverse myelitis (ATM) is a severe disorder; recovery requires several months and often leaves neurologic residua. To determine what features of patients with acute transverse myelitis significantly influence prognosis, the authors reviewed reports of ATM in Japanese children published in the last 15 years (from 1987 to 2001).


Journal of Paediatrics and Child Health | 2006

Effect of formula thickened with locust bean gum on gastric emptying in infants

Reiko Miyazawa; Takeshi Tomomasa; Hiroaki Kaneko; Akihiro Morikawa

Aim:  We investigated the effects of milk‐based formulas thickened with two different concentrations of locust bean gum on gastric emptying in infants with recurrent regurgitation episodes.


BMC Gastroenterology | 2008

Effects of pectin liquid on gastroesophageal reflux disease in children with cerebral palsy

Reiko Miyazawa; Takeshi Tomomasa; Hiroaki Kaneko; Hirokazu Arakawa; Nobuzo Shimizu; Akihiro Morikawa

BackgroundThe use of thickeners is a standard therapy for decreasing episodes of regurgitation or vomiting in infants. However, it remains to be investigated whether thickener is effective for vomiting and/or chronic respiratory symptoms in children with cerebral palsy.MethodsWe enrolled 18 neurologically impaired children caused by cerebral palsy, with gastroesophageal reflux disease. In the first part of this study (pH monitoring), subjects were randomly allocated to two groups: fed with a high-pectin diet [enteral formula: pectin liquid = 2:1 (v/v)], or a low-pectin diet [enteral formula: pectin liquid = 3:1 (v/v)]. Two-channel esophageal pH monitoring was performed over 48 h. In the second part (clinical trial), subjects were fed a high- or low-pectin diet and non-pectin diet for 4 weeks in a crossover manner. Nurses recorded the feeding volume, number of episodes of vomiting, volume of gastric residue, episodes of cough and wheeze, frequency of using oxygen for dyspnea, and the day when the child could return to school. Cough and wheeze were recorded as a cough-score.ResultsThe median value for the % time pH < 4 at the lower and upper esophagus was significantly decreased with a high-pectin diet [9.2% (6.2–22.6) vs. 5.0% (3.1–13.1); P < 0.01, 3.8% (2.9–11.2) vs. 1.6% (0.9–8.9); P < 0.01 (interquartile range), non-pectin and high-pectin, respectively]. The number of reflux episodes per day and duration of longest reflux were decreased significantly with a high-pectin, but not with a low-pectin diet. The median number of episodes of vomiting decreased significantly with a high-pectin diet [2.5/week (1.0–5.0) vs. 1.0 (1.0–1.5), P < 0.05]. The median cough-score was significantly decreased by both concentrations of pectin [8.5/week (1.0–11.5) vs. 2.0/week (0.0–3.0), fed with a high-pectin diet; 7.0/week (1.0–14.5) vs. 1.0/w (0.0–5.0), fed with a low-pectin diet, P < 0.05].ConclusionPectin liquid partially decreased gastroesophageal reflux as measured by eshophageal pH monitoring, and might improve vomiting and respiratory symptoms in children with cerebral palsy.Trial registrationISRCTN19787793


Acta Paediatrica | 2007

Effect of formula thickened with reduced concentration of locust bean gum on gastroesophageal reflux.

Reiko Miyazawa; Takeshi Tomomasa; Hiroaki Kaneko; Hirokazu Arakawa; Akihiro Morikawa

Aim: Previous studies showed that HL‐350, a formula thickened with a reduced concentration of locust bean gum, decreased frequent regurgitation in 4‐month old infants with reflux. In this study, we investigated the effect of HL‐350 in younger infants.


Journal of Pediatric Gastroenterology and Nutrition | 2004

Effect of locust bean gum in anti-regurgitant milk on the regurgitation in uncomplicated gastroesophageal reflux

Reiko Miyazawa; Takeshi Tomomasa; Hiroaki Kaneko; Akihiro Morikawa

Objectives: To evaluate the efficacy of anti-regurgitant milk (AR milk) with reduced concentration of locust bean gum (LBG) compared with the usual commercially available concentration of this thickener. Methods: Thirty infants with daily regurgitation but no other medical problems were randomly assigned to one of two groups. Infants in group A (n = 16) were fed either HL-450, an AR milk thickened with a commonly used concentration of LBG (0.45 g/100 mL) or control milk (HL-00; no LBG) in a crossover manner for periods of 1 week. The order of milk was randomly chosen for each subject. Infants in group B (n = 14) were fed HL-350, an AR milk with a reduced LBG concentration (0.35 g/100 mL), or HL-00 in the same crossover fashion. The number of episodes of regurgitation, feeding time, and body weight gain were recorded. Three infants in group B did not complete the protocol and were excluded. Results: Both AR formulas decreased the number of regurgitation episodes by approximately 50% compared with control. Five mothers who gave their infants HL-450 and no mothers who fed their children HL-350 reported that the infants had difficulty sucking the formula through the nipple. Thirteen (81.3%) mothers who used HL-450 and 9 (81.8%) mothers who used HL-350 preferred the AR milk to the control milk. Conclusions: An AR milk with reduced LBG was as effective in reducing regurgitation as one with the usually available concentration of LBG.


Journal of Gastroenterology | 2004

Pharmacobezoar complicating treatment with sodium alginate

Hiroaki Kaneko; Takeshi Tomomasa; Yumi Kubota; Makoto Todokoro; Masahiko Kato; Reiko Miyazawa; Tomoko Suzuki; Yukie Hatori; Fumio Kunimoto; Koujirou Yamamoto; Akihiro Morikawa

We encountered a gastric bezoar that had developed in a 9-year-old girl treated with sodium alginate (Alloid G) for acute gastritis associated with systemic lupus erythematosus. A hard mass palpated in the left upper abdomen proved, upon gastric endoscopy, to be an intragastric foreign body. Sodium alginate was detected in an analysis of a sample from this bezoar. In an in vitro simulation, sodium alginate solidified when mixed with the patient’s other medicines. The bezoar caused no complications, and disappeared spontaneously after discontinuation of the medications. This case indicates that this sodium alginate preparation, Alloid G, can be a cause of pharmacobezoar.


World Journal of Gastroenterology | 2011

Serum magnesium concentration in children with functional constipation treated with magnesium oxide

Maiko Tatsuki; Reiko Miyazawa; Takeshi Tomomasa; Takashi Ishige; Tomoko Nakazawa; Hirokazu Arakawa

AIM To determine whether hypermagnesemia recently reported in adult patients possibly develops in children with functional constipation taking daily magnesium oxide. METHODS We enrolled 120 patients (57 male and 63 female) aged 1-14 years old (median: 4.7 years) with functional constipation from 13 hospitals and two private clinics. All patients fulfilled the Rome III criteria for functional constipation and were treated with daily oral magnesium oxide for at least 1 mo. The median treatment dose was 600 (500-800) mg/d. Patients were assessed by an interview and laboratory examination to determine possible hypermagnesemia. Serum magnesium concentration was also measured in sex- and age-matched control subjects (n = 38). RESULTS In the constipation group, serum magnesium concentration [2.4 (2.3-2.5) mg/dL, median and interquartile range] was significantly greater than that of the control group [2.2 (2.0-2.2) mg/dL] (P < 0.001). The highest value was 3.2 mg/dL. Renal magnesium clearance was significantly increased in the constipation group. Serum magnesium concentration in the constipation group decreased significantly with age (P < 0.01). There was no significant correlation between the serum level of magnesium and the duration of treatment with magnesium oxide or the daily dose. None of the patients had side effects associated with hypermagnesemia. CONCLUSION Serum magnesium concentration increased significantly, but not critically, after daily treatment with magnesium oxide in constipated children with normal renal function.


Hepatology Research | 2011

Efficacy of pegylated interferon-α2a monotherapy in Japanese children with chronic hepatitis C

Tomoyuki Tsunoda; Ayano Inui; Yuri Etani; Yuki Kiyohara; Tokio Sugiura; Koichi Ito; Reiko Miyazawa; Ikuo Nagata; Shinobu Ida; Tomoo Fujisawa

Aim:  There is little information available on the efficacy of pegylated interferon (PEG IFN) therapy for children with chronic hepatitis C. The aim of this study was to evaluate the efficacy and tolerability of PEG IFN‐α2a monotherapy for children infected by chronic hepatitis C virus (HCV).

Collaboration


Dive into the Reiko Miyazawa's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge